Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428678 | 0.91 | HPGD (0.51) | KDM4EPKMHPGDALDH1A1TSHR | |
| SCHEMBL31428699 | 0.87 | HTR2C (0.53) | KDM4EPKMHPGDALDH1A1TSHR | |
| SCHEMBL31428810 | 0.86 | HPGD (0.48) | KDM4EPKMHPGDALDH1A1TSHR | |
| SCHEMBL31429016 | 0.85 | HTR2C (0.54) | KDM4EHPGDALDH1A1 | |
| SCHEMBL31428513 | 0.84 | PDCD1 (0.53) | KDM4EPKMHPGDALDH1A1TSHR | |
| SCHEMBL31428537 | 0.84 | PDCD1 (0.52) | KDM4EPKMHPGDALDH1A1TSHR | |
| SCHEMBL31429044 | 0.83 | HPGD (0.50) | HPGDALDH1A1TSHRLMNACNR1 | |
| SCHEMBL31428749 | 0.83 | ALDH1A1 (0.46) | KDM4EHPGDALDH1A1TSHRUSP2 | |
| SCHEMBL31428449 | 0.83 | HPGD (0.53) | HPGDALDH1A1TSHRLMNACNR1 | |
| SCHEMBL24975622 | 0.82 | MAPK10 (0.49) | KDM4EPKMHPGDPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | KDM4E 2663/4885PKM 4478/4885HPGD 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.